IDEX Q2 2026: Sales Climb 6%, EPS Hits $1.93; IEEPA Tariff Refunds Lift Margins
IEX sits 46% above its 52-week low of $157.25 on elevated volume (2.2× avg).
Summary
IDEX posted Q2 2026 net sales of $920.6M (+6% YoY) and diluted EPS of $1.93 (+11%), helped by a $22M IEEPA tariff refund. Organic growth reached 5%, led by Health & Science Technologies.
Key Events · Earnings and Guidance · IEX
-
Q2 Sales and Earnings Beat
Driven by 5% organic growth, net sales reached $920.6M (+6% YoY) and diluted EPS came in at $1.93 (+11% YoY), surpassing prior-year results.
-
IEEPA Tariff Refund Windfall
A $22.0M refund of previously paid IEEPA tariffs reduced cost of sales, adding $0.08 to EPS and boosting gross margin by 150 bps.
-
Health & Science Technologies Leads Growth
Fueled by AI-driven demand in data centers and semiconductors, HST segment sales rose 14% to $414M, with Adjusted EBITDA up 26%.
-
Capital Return to Shareholders
During H1 2026, IDEX repurchased $151.3M in shares (0.7M shares) and paid $106.7M in dividends, leaving $774.7M remaining under buyback authorization.
Analysis · IEX · Technology
A strong second quarter saw net sales advance 6% to $920.6 million, while diluted EPS rose 11% to $1.93. The performance was amplified by a one-time $22.0 million IEEPA tariff refund that lowered cost of sales, contributing roughly $0.08 to EPS. Organic sales grew 5%, with AI-related demand in data centers and semiconductors propelling the Health & Science Technologies segment. Shareholders received $131 million through buybacks and dividends, and the balance sheet remained robust—$621 million in cash and $530 million available under the revolving credit facility. No material changes to risk factors or critical accounting estimates were disclosed.
At the time of this filing, IEX was trading at $229.52 on NYSE in the Technology sector, with a market capitalization of approximately $17B. The 52-week trading range was $157.25 to $243.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.